{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:48Z","timestamp":1792783428332,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kanazawa University","id":[{"id":"https:\/\/ror.org\/02hwp6a56","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Bone scan indexes (BSIs) are frequently applied in Japan, Europe and the USA. The BONENAVI (Japan) and aBSI (Europe and USA) software programs were developed based on different training and validation datasets to calculate BSIs. However, whether they are compatible has not been systematically determined. We compared BSIs generated by these programs in a patient cohort to clarify correlations between them.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 339 scintigraphic data from 34 patients (mean age, 69.9\u2009\u00b1\u20099.1 [48\u201389] y) with prostate cancer who underwent whole-body bone scintigraphy to evaluate metastatic bone disease. Anterior and posterior whole-body scans with\n                      <jats:sup>99m<\/jats:sup>\n                      Tc-methylene-diphosphonate (MDP) were processed then BSIs were computed by aBSI and BONENAVI. Systematic differences between aBSI and BONENAVI were evaluated using Pearson\u2019s correlation coefficients and Bland\u2013Altman analysis. We also categorized BSIs during follow-up as decreased, unchanged, or increased, and evaluated agreement between longitudinal changes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean number of bone scans per patient was 10.0\u2009\u00b1\u20096.8 (1\u221226), and longitudinal changes in BSIs were evaluated using 305 pairs of follow-up studies. The automatic BSIs from aBSI and BONENAVI were 3.23% \u00b1 3.47% and 2.91% \u00b1 2.84%, respectively. Both strongly correlated (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.947,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Bland\u2013Altman plots revealed that aBSI tended to yield slightly higher BSIs (mean difference, +\u20090.31% (95% CI, 0.19\u22120.44,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). A subgroup analysis of BSIs\u2009&gt;\u20097% revealed higher automatic BSIs from aBSI than BONENAVI (mean difference, +\u20091.57%; 95% CI, 0.99\u22122.15;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The rate of longitudinal changes in BSI during follow-up substantially agreed (78.7% vs. 76.4% with respective thresholds of \u00b1\u20090.5% and \u00b1\u20090.3% (\u03ba\u2009=\u20090.63, Cramer\u2019s V\u2009=\u20090.65,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001 for both).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The aBSI and BONENAVI BSIs computed by the software programs strongly correlated and longitudinal changes during follow-up studies generally concurred. However, BSIs from aBSI tended to be higher among patients with an increased disease burden compared with BONENAVI. Clinicians and investigators should be aware of these differences when interpreting or comparing results among software programs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12149-026-02244-7","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:14:51Z","timestamp":1780982091000},"page":"1253-1261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of automated bone scan indexes in patients with prostate cancer: aBSI and BONENAVI"],"prefix":"10.1007","volume":"40","author":[{"given":"Takeshi","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7188-8746","authenticated-orcid":false,"given":"Kenichi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Kinuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"2244_CR1","first-page":"1765","volume":"4","author":"M Imbriaco","year":"1998","unstructured":"Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res. 1998;4:1765\u201372.","journal-title":"Clin Cancer Res"},{"key":"2244_CR2","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.2967\/jnumed.108.055061","volume":"49","author":"M Sadik","year":"2008","unstructured":"Sadik M, Hamadeh I, Nordblom P, Suurkula M, Hoglund P, Ohlsson M, et al. Computer-assisted interpretation of planar whole-body bone scans. J Nucl Med. 2008;49:1958\u201365.","journal-title":"J Nucl Med"},{"key":"2244_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/2191-219X-3-83","volume":"3","author":"K Nakajima","year":"2013","unstructured":"Nakajima K, Nakajima Y, Horikoshi H, Ueno M, Wakabayashi H, Shiga T, et al. Enhanced diagnostic accuracy for quantitative bone scan using an artificial neural network system: a Japanese multi-center database project. EJNMMI Res. 2013;3:83.","journal-title":"EJNMMI Res"},{"key":"2244_CR4","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/iju.13386","volume":"24","author":"K Nakajima","year":"2017","unstructured":"Nakajima K, Edenbrandt L, Mizokami A. Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer. Int J Urol. 2017;24:668\u201373.","journal-title":"Int J Urol"},{"key":"2244_CR5","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/iju.14614","volume":"28","author":"K Nakajima","year":"2021","unstructured":"Nakajima K, Mizokami A, Matsuyama H, Ichikawa T, Kaneko G, Takahashi S, et al. Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study. Int J Urol. 2021;28:955\u201363.","journal-title":"Int J Urol"},{"key":"2244_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13550-016-0173-z","volume":"6","author":"A Anand","year":"2016","unstructured":"Anand A, Morris MJ, Larson SM, Minarik D, Josefsson A, Helgstrand JT, et al. Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. EJNMMI Res. 2016;6:23.","journal-title":"EJNMMI Res"},{"key":"2244_CR7","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.clgc.2016.12.020","volume":"15","author":"Y Miyoshi","year":"2017","unstructured":"Miyoshi Y, Uemura K, Kawahara T, Yoneyama S, Hattori Y, Teranishi JI, et al. Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate. Clin Genitourin Cancer. 2017;15:472\u20138.","journal-title":"Clin Genitourin Cancer"},{"key":"2244_CR8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.euf.2016.02.013","volume":"2","author":"M Reza","year":"2016","unstructured":"Reza M, Ohlsson M, Kaboteh R, Anand A, Franck-Lissbrant I, Damber J-E, et al. Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice. Eur Urol Focus. 2016;2:540\u20136.","journal-title":"Eur Urol Focus"},{"key":"2244_CR9","doi-asserted-by":"publisher","first-page":"E628","DOI":"10.1111\/j.1464-410X.2012.11355.x","volume":"110","author":"Y Mitsui","year":"2012","unstructured":"Mitsui Y, Shiina H, Yamamoto Y, Haramoto M, Arichi N, Yasumoto H, et al. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int. 2012;110:E628\u201334.","journal-title":"BJU Int"},{"key":"2244_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/s12885-018-4401-y","volume":"18","author":"K Uemura","year":"2018","unstructured":"Uemura K, Miyoshi Y, Kawahara T, Ryosuke J, Yamashita D, Yoneyama S, et al. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel. BMC Cancer. 2018;18:501.","journal-title":"BMC Cancer"},{"key":"2244_CR11","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.21873\/anticanres.13377","volume":"39","author":"S Kadomoto","year":"2019","unstructured":"Kadomoto S, Yaegashi H, Nakashima K, Iijima M, Kawaguchi S, Nohara T, et al. Quantification of Bone Metastasis of Castration-resistant Prostate Cancer After Enzalutamide and Abiraterone Acetate Using Bone Scan Index on Bone Scintigraphy. Anticancer Res. 2019;39:2553\u20139.","journal-title":"Anticancer Res"},{"key":"2244_CR12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.clgc.2022.02.002","volume":"20","author":"A Anand","year":"2022","unstructured":"Anand A, Heller G, Fox J, Danila DC, Bjartell A, Edenbrandt L, et al. Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2022;20:270\u20137.","journal-title":"Clin Genitourin Cancer"},{"key":"2244_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.eururo.2012.01.037","volume":"62","author":"D Ulmert","year":"2012","unstructured":"Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol. 2012;62:78\u201384.","journal-title":"Eur Urol"},{"key":"2244_CR14","doi-asserted-by":"crossref","unstructured":"Kaboteh R, Minarik D, Reza M, Sadik M, Tragardh E. Evaluation of changes in Bone Scan Index at different acquisition time-points in bone scintigraphy. Clin Physiol Funct Imaging. 2018.","DOI":"10.1111\/cpf.12518"},{"key":"2244_CR15","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s12149-024-01914-8","volume":"38","author":"X Zhang","year":"2024","unstructured":"Zhang X, Nakajima K, Mizokami A, Horikoshi H, Nishimoto K, Hashine K, et al. Flare phenomenon visualized by 99mTc-bone scintigraphy has prognostic value for patients with metastatic castration-resistant prostate cancer. Ann Nucl Med. 2024;38:428\u201340.","journal-title":"Ann Nucl Med"},{"key":"2244_CR16","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s12149-012-0620-5","volume":"26","author":"H Horikoshi","year":"2012","unstructured":"Horikoshi H, Kikuchi A, Onoguchi M, Sjostrand K, Edenbrandt L. Computer-aided diagnosis system for bone scintigrams from Japanese patients: importance of training database. Ann Nucl Med. 2012;26:622\u20136.","journal-title":"Ann Nucl Med"},{"key":"2244_CR17","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12149-015-0988-0","volume":"29","author":"M Koizumi","year":"2015","unstructured":"Koizumi M, Miyaji N, Murata T, Motegi K, Miwa K, Koyama M, et al. Evaluation of a revised version of computer-assisted diagnosis system, BONENAVI version 2.1.7, for bone scintigraphy in cancer patients. Ann Nucl Med. 2015;29:659\u201365.","journal-title":"Ann Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02244-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02244-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02244-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:06:40Z","timestamp":1790644000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02244-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2244"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02244-7","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K. Nakajima belonged to an endowed department supported by PDRadiopharma, Inc. (Tokyo, Japan), Nihon Medi-Physics (Tokyo, Japan), and Siemens Healthcare (Tokyo, Japan), until March 2024. J. Richter is employed by EXINI Diagnostics, AB, Lund, Sweden. SCETI KK (Tokyo, Japan) provided funding support to the Department of Nuclear Medicine, Kanazawa University. The authors declare no other conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the institutional review board of Kanazawa University. The requirement for informed consent was waived due to the retrospective nature of the study (Approved No. 114831, 2024\u2009\u2212\u2009379).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}